Friday, 21 December 2018

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug, Bavencio, to treat a form of ovarian cancer in previously untreated patients.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)